0000851520false--01-02Q259.559.559.559.559.5http://fasb.org/srt/2025#ChiefExecutiveOfficerMember110000851520expo:UnvestedRestrictedStockAwardsMember2025-01-042025-07-040000851520us-gaap:OperatingSegmentsMember2025-04-052025-07-040000851520us-gaap:OperatingSegmentsMember2023-12-302024-06-280000851520us-gaap:TimeAndMaterialsContractMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberexpo:EngineeringAndOtherScientificMember2025-04-052025-07-040000851520us-gaap:FairValueInputsLevel2Member2025-01-0300008515202025-07-040000851520us-gaap:AdditionalPaidInCapitalMember2024-03-302024-06-280000851520us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2025-07-040000851520expo:CatherineFordCorriganMember2025-07-040000851520us-gaap:OperatingSegmentsMemberexpo:EngineeringAndOtherScientificMember2025-01-042025-07-040000851520us-gaap:AdditionalPaidInCapitalMember2023-12-290000851520us-gaap:SalesRevenueNetMemberexpo:SingleClientMemberus-gaap:RevenueFromRightsConcentrationRiskMember2025-01-042025-07-040000851520us-gaap:TreasuryStockCommonMember2025-01-030000851520us-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberexpo:EngineeringAndOtherScientificMemberus-gaap:FixedPriceContractMember2025-04-052025-07-040000851520us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-052025-07-040000851520us-gaap:TimeAndMaterialsContractMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMember2025-01-042025-07-040000851520us-gaap:UnbilledRevenuesMember2025-07-040000851520us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2025-01-030000851520us-gaap:FairValueInputsLevel1Memberus-gaap:FixedIncomeSecuritiesMember2025-07-040000851520us-gaap:CashAndCashEquivalentsMember2025-07-040000851520us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2025-01-030000851520us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-040000851520us-gaap:RestrictedStockUnitsRSUMember2025-04-052025-07-040000851520us-gaap:TimeAndMaterialsContractMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMember2023-12-302024-06-280000851520expo:EnvironmentalAndHealthMemberus-gaap:OperatingSegmentsMember2025-04-052025-07-040000851520expo:UnvestedRestrictedStockAwardsMembersrt:MinimumMember2025-01-042025-07-040000851520us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMember2025-07-040000851520us-gaap:TimeAndMaterialsContractMemberexpo:EnvironmentalAndHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMember2025-04-052025-07-040000851520us-gaap:TimeAndMaterialsContractMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberexpo:EngineeringAndOtherScientificMember2023-12-302024-06-280000851520us-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberexpo:EngineeringAndOtherScientificMemberus-gaap:FixedPriceContractMember2023-12-302024-06-280000851520us-gaap:AdditionalPaidInCapitalMember2025-04-040000851520us-gaap:CommonStockMember2024-06-280000851520us-gaap:AdditionalPaidInCapitalMember2024-06-280000851520expo:EnvironmentalAndHealthMemberus-gaap:OperatingSegmentsMember2025-01-042025-07-040000851520us-gaap:OperatingSegmentsMember2024-03-302024-06-280000851520us-gaap:TreasuryStockCommonMember2023-12-290000851520us-gaap:CommonStockMember2025-07-040000851520us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-290000851520us-gaap:RestrictedStockUnitsRSUMember2025-01-042025-07-040000851520us-gaap:FairValueInputsLevel2Member2025-07-040000851520us-gaap:TreasuryStockCommonMember2024-03-290000851520expo:EnvironmentalAndHealthMemberus-gaap:OperatingSegmentsMember2023-12-302024-06-280000851520expo:UnvestedStockOptionsMembersrt:MinimumMember2025-01-042025-07-040000851520us-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberus-gaap:FixedPriceContractMember2025-01-042025-07-040000851520us-gaap:BilledRevenuesMember2025-01-0300008515202024-03-302024-06-280000851520expo:OfficeLaboratoryAndStorageSpaceMembersrt:MaximumMember2025-07-040000851520us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2025-01-0300008515202024-06-280000851520us-gaap:BilledRevenuesMember2025-07-040000851520us-gaap:RestrictedStockUnitsRSUMember2024-03-302024-06-280000851520us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2025-07-040000851520us-gaap:FairValueInputsLevel1Member2025-01-030000851520us-gaap:SalesRevenueNetMemberexpo:SingleClientMemberus-gaap:RevenueFromRightsConcentrationRiskMember2025-04-052025-07-040000851520us-gaap:OtherOperatingIncomeExpenseMember2025-04-052025-07-040000851520us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2025-01-030000851520us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-302024-06-280000851520us-gaap:FairValueInputsLevel1Member2025-07-040000851520us-gaap:CashEquivalentsMember2025-01-030000851520expo:OfficeLaboratoryAndStorageSpaceMembersrt:MinimumMember2025-07-040000851520us-gaap:AdditionalPaidInCapitalMember2025-01-042025-04-040000851520us-gaap:TreasuryStockCommonMember2024-06-280000851520us-gaap:FairValueInputsLevel3Memberus-gaap:FixedIncomeSecuritiesMember2025-07-040000851520us-gaap:TimeAndMaterialsContractMemberexpo:EnvironmentalAndHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMember2023-12-302024-06-280000851520us-gaap:CorporateNonSegmentMember2025-01-042025-07-040000851520expo:PhoenixArizonaMember2025-01-042025-07-040000851520us-gaap:TreasuryStockCommonMember2025-07-040000851520us-gaap:TimeAndMaterialsContractMemberexpo:EnvironmentalAndHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMember2024-03-302024-06-280000851520us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-042025-04-040000851520us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2025-07-040000851520us-gaap:TimeAndMaterialsContractMemberexpo:EnvironmentalAndHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMember2025-01-042025-07-040000851520us-gaap:RetainedEarningsMember2025-01-030000851520us-gaap:RetainedEarningsMember2024-03-290000851520us-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberus-gaap:FixedPriceContractMemberexpo:EngineeringAndOtherScientificMember2025-01-042025-07-040000851520expo:OfficeLaboratoryAndStorageSpaceMember2025-07-040000851520us-gaap:CommonStockMember2023-12-2900008515202025-01-030000851520us-gaap:EquitySecuritiesMember2025-07-040000851520expo:UnvestedRestrictedStockAwardsMember2025-04-052025-07-0400008515202025-04-052025-07-0400008515202024-03-290000851520us-gaap:RetainedEarningsMember2024-03-302024-06-280000851520us-gaap:TimeAndMaterialsContractMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberexpo:EngineeringAndOtherScientificMember2025-01-042025-07-040000851520us-gaap:OperatingSegmentsMember2025-01-042025-07-040000851520expo:VestedRestrictedStockAwardsMember2023-12-302024-06-280000851520us-gaap:FixedIncomeSecuritiesMember2025-01-030000851520us-gaap:CashMember2025-01-030000851520us-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberus-gaap:FixedPriceContractMemberexpo:EngineeringAndOtherScientificMember2024-03-302024-06-280000851520us-gaap:FairValueInputsLevel3Memberus-gaap:FixedIncomeSecuritiesMember2025-01-030000851520us-gaap:AdditionalPaidInCapitalMember2025-01-030000851520expo:PhoenixArizonaMember2025-07-040000851520us-gaap:RetainedEarningsMember2025-04-052025-07-040000851520us-gaap:EmployeeStockOptionMember2025-01-042025-07-040000851520us-gaap:TreasuryStockCommonMember2025-04-052025-07-040000851520us-gaap:SubsequentEventMemberexpo:O2025Q3DividendsMember2025-07-312025-07-3100008515202023-12-302024-03-290000851520us-gaap:TreasuryStockCommonMember2025-01-042025-04-040000851520us-gaap:SalesRevenueNetMemberexpo:SingleClientMemberus-gaap:RevenueFromRightsConcentrationRiskMember2024-03-302024-06-280000851520us-gaap:TimeAndMaterialsContractMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberexpo:EngineeringAndOtherScientificMember2024-03-302024-06-280000851520us-gaap:FairValueInputsLevel3Member2025-07-0400008515202025-01-042025-04-040000851520us-gaap:FairValueInputsLevel2Memberus-gaap:FixedIncomeSecuritiesMember2025-01-030000851520us-gaap:RetainedEarningsMember2025-01-042025-04-040000851520us-gaap:TimeAndMaterialsContractMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMember2025-04-052025-07-040000851520us-gaap:EquitySecuritiesMember2025-01-030000851520us-gaap:UnbilledRevenuesMember2025-01-030000851520us-gaap:OperatingSegmentsMemberexpo:EngineeringAndOtherScientificMember2023-12-302024-06-280000851520us-gaap:OtherIncomeMember2025-04-052025-07-040000851520us-gaap:CorporateNonSegmentMember2025-04-052025-07-040000851520us-gaap:RetainedEarningsMember2025-04-040000851520expo:EnvironmentalAndHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberus-gaap:FixedPriceContractMember2023-12-302024-06-280000851520us-gaap:TreasuryStockCommonMember2025-04-040000851520us-gaap:FairValueInputsLevel2Memberus-gaap:FixedIncomeSecuritiesMember2025-07-040000851520us-gaap:AdditionalPaidInCapitalMember2023-12-302024-03-290000851520us-gaap:RetainedEarningsMember2023-12-302024-03-290000851520us-gaap:CashAndCashEquivalentsMember2025-01-030000851520us-gaap:OperatingSegmentsMemberexpo:EngineeringAndOtherScientificMember2024-03-302024-06-280000851520expo:UnvestedRestrictedStockAwardsMember2024-03-302024-06-2800008515202025-04-040000851520us-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberus-gaap:FixedPriceContractMember2024-03-302024-06-280000851520expo:UnvestedRestrictedStockAwardsMember2023-12-302024-06-280000851520expo:EnvironmentalAndHealthMemberus-gaap:OperatingSegmentsMember2024-03-302024-06-280000851520us-gaap:RestrictedStockUnitsRSUMember2023-12-302024-06-280000851520us-gaap:EmployeeStockOptionMember2023-12-302024-06-280000851520us-gaap:OtherIncomeMember2024-03-302024-06-280000851520us-gaap:RetainedEarningsMember2024-06-280000851520us-gaap:FairValueInputsLevel3Member2025-01-030000851520us-gaap:EmployeeStockOptionMember2024-03-302024-06-280000851520us-gaap:MoneyMarketFundsMember2025-01-030000851520us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-0300008515202023-12-290000851520expo:VestedRestrictedStockAwardsMember2025-04-052025-07-040000851520us-gaap:TreasuryStockCommonMember2023-12-302024-03-290000851520srt:MaximumMember2025-01-042025-07-040000851520us-gaap:CorporateNonSegmentMember2023-12-302024-06-280000851520us-gaap:OtherOperatingIncomeExpenseMember2024-03-302024-06-280000851520us-gaap:MoneyMarketFundsMember2025-07-040000851520us-gaap:CashMember2025-07-040000851520us-gaap:CommonStockMember2025-04-040000851520us-gaap:TreasuryStockCommonMember2024-03-302024-06-2800008515202025-08-010000851520expo:EnvironmentalAndHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberus-gaap:FixedPriceContractMember2024-03-302024-06-280000851520us-gaap:AdditionalPaidInCapitalMember2025-04-052025-07-040000851520us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2025-01-030000851520us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2025-01-030000851520us-gaap:OtherOperatingIncomeExpenseMember2025-01-042025-07-040000851520us-gaap:RetainedEarningsMember2025-07-0400008515202023-12-302024-06-280000851520expo:VestedRestrictedStockAwardsMember2025-01-042025-07-040000851520us-gaap:OtherIncomeMember2025-01-042025-07-040000851520us-gaap:AdditionalPaidInCapitalMember2025-07-040000851520us-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberus-gaap:FixedPriceContractMember2023-12-302024-06-2800008515202025-01-042025-07-040000851520us-gaap:AdditionalPaidInCapitalMember2024-03-290000851520us-gaap:CommonStockMember2025-01-030000851520us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2025-07-040000851520us-gaap:CorporateNonSegmentMember2024-03-302024-06-280000851520expo:EnvironmentalAndHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberus-gaap:FixedPriceContractMember2025-04-052025-07-040000851520us-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberus-gaap:FixedPriceContractMember2025-04-052025-07-040000851520us-gaap:RetainedEarningsMember2023-12-290000851520us-gaap:EmployeeStockOptionMember2025-04-052025-07-040000851520us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-040000851520us-gaap:OtherOperatingIncomeExpenseMember2023-12-302024-06-280000851520us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-302024-03-290000851520expo:EnvironmentalAndHealthMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMemberus-gaap:FixedPriceContractMember2025-01-042025-07-040000851520us-gaap:CashEquivalentsMember2025-07-040000851520us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-290000851520us-gaap:OtherIncomeMember2023-12-302024-06-280000851520us-gaap:SalesRevenueNetMemberexpo:SingleClientMemberus-gaap:RevenueFromRightsConcentrationRiskMember2023-12-302024-06-280000851520us-gaap:TimeAndMaterialsContractMemberus-gaap:SalesRevenueNetMemberus-gaap:RevenueFromRightsConcentrationRiskMember2024-03-302024-06-280000851520expo:VestedRestrictedStockAwardsMember2024-03-302024-06-280000851520us-gaap:OperatingSegmentsMemberexpo:EngineeringAndOtherScientificMember2025-04-052025-07-040000851520us-gaap:FairValueInputsLevel1Memberus-gaap:FixedIncomeSecuritiesMember2025-01-030000851520expo:CatherineFordCorriganMember2025-04-052025-07-040000851520us-gaap:FixedIncomeSecuritiesMember2025-07-040000851520us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-280000851520us-gaap:CommonStockMember2024-03-290000851520us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2025-07-04utr:acreexpo:Segmentxbrli:purexbrli:sharesiso4217:USDxbrli:sharesexpo:Optionexpo:Clientexpo:Stateiso4217:USD

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended July 4, 2025

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____________ to___________

Commission File Number 0-18655

EXPONENT, INC.

(Exact name of registrant as specified in its charter)

 

delaware

 

77-0218904

(State or other jurisdiction of

 

(I.R.S. Employer Identification No.)

incorporation or organization)

 

 

 

 

 

149 COMMONWEALTH DRIVE,

MENLO PARK, California

 

94025

(Address of principal executive office)

 

(Zip Code)

 

(650) 326-9400

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol

 

Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

EXPO

 

Nasdaq Global Select Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes

 

 

No

 

 

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

 

Yes

 

 

No

 

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

Emerging growth company

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes

 

 

No

 

 

 

 

 

As of August 1, 2025, the latest practicable date, the registrant had 50,501,135 shares of common stock outstanding.

 

 


 

EXPONENT, INC.

FORM 10-Q

TABLE OF CONTENTS

 

 

 

 

 

Page

 

 

 

 

 

PART I – FINANCIAL INFORMATION

 

3

 

 

 

 

 

Item 1.

 

Financial Statements (unaudited):

 

3

 

 

 

 

 

 

 

Condensed Consolidated Balance Sheets July 4, 2025 and January 3, 2025

 

3

 

 

 

 

 

 

 

Condensed Consolidated Statements of Income For the Three and Six Months Ended July 4, 2025 and June 28, 2024

 

4

 

 

 

 

 

 

 

Condensed Consolidated Statements of Comprehensive Income For the Three and Six Months Ended July 4, 2025 and June 28, 2024

 

5

 

 

 

 

 

 

 

Condensed Consolidated Statements of Stockholders’ Equity For the Three and Six Months Ended July 4, 2025 and June 28, 2024

 

6

 

 

 

 

 

 

 

Condensed Consolidated Statements of Cash Flows For the Six Months Ended July 4, 2025 and June 28, 2024

 

8

 

 

 

 

 

 

 

Notes to Unaudited Condensed Consolidated Financial Statements

 

9

 

 

 

 

 

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

20

 

 

 

 

 

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

 

29

 

 

 

 

 

Item 4.

 

Controls and Procedures

 

29

 

 

 

 

 

PART II – OTHER INFORMATION

 

30

 

 

 

 

 

Item 1.

 

Legal Proceedings

 

30

 

 

 

 

 

Item 1A.

 

Risk Factors

 

30

 

 

 

 

 

Item 2.

 

Unregistered Sales of Equity Securities and Use of Proceeds

 

30

 

 

 

 

 

Item 3.

 

Defaults Upon Senior Securities

 

30

 

 

 

 

 

Item 4.

 

Mine Safety Disclosures

 

30

 

 

 

 

 

Item 5.

 

Other Information

 

30

 

 

 

 

 

Item 6.

 

Exhibits

 

32

 

 

 

 

 

 

 

Signatures

 

33

 

- 2 -


 

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

EXPONENT, INC.

Condensed Consolidated Balance Sheets

July 4, 2025 and January 3, 2025

(unaudited)

 

(In thousands, except par value)

 

July 4, 2025
(Unaudited)

 

 

January 3,
2025

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

231,801

 

 

$

258,901

 

Accounts receivable, net of allowance for contract losses and doubtful accounts
   of $
6,180 and $6,141 at July 4, 2025 and January 3, 2025, respectively

 

 

171,012

 

 

 

161,407

 

Prepaid expenses and other current assets

 

 

22,838

 

 

 

26,573

 

Total current assets

 

 

425,651

 

 

 

446,881

 

 

 

 

 

 

 

 

Property, equipment and leasehold improvements, net of accumulated depreciation and
   amortization of $
117,180 and $112,202 at July 4, 2025 and January 3, 2025,
   respectively

 

 

71,637

 

 

 

73,007

 

Operating lease right-of-use assets

 

 

72,338

 

 

 

75,248

 

Goodwill

 

 

8,607

 

 

 

8,607

 

Deferred income taxes

 

 

60,221

 

 

 

57,127

 

Deferred compensation plan assets

 

 

114,929

 

 

 

110,259

 

Other assets

 

 

6,047

 

 

 

6,141

 

Total assets

 

$

759,430

 

 

$

777,270

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

$

25,268

 

 

$

22,136

 

Accrued payroll and employee benefits

 

 

92,197

 

 

 

119,285

 

Deferred revenues

 

 

11,653

 

 

 

16,369

 

Operating lease liabilities

 

 

5,851

 

 

 

5,393

 

Total current liabilities

 

 

134,969

 

 

 

163,183

 

 

 

 

 

 

 

 

Other liabilities

 

 

4,658

 

 

 

4,289

 

Deferred compensation plan liabilities

 

 

117,555

 

 

 

112,646

 

Operating lease liabilities

 

 

74,472

 

 

 

76,084

 

Total liabilities

 

 

331,654

 

 

 

356,202

 

Stockholders’ equity:

 

 

 

 

 

 

Common stock, $0.001 par value; 120,000 shares authorized; 65,707 shares issued
   at July 4, 2025 and January 3, 2025

 

 

66

 

 

 

66

 

Additional paid-in capital

 

 

364,304

 

 

 

345,689

 

Accumulated other comprehensive loss

 

 

 

 

 

 

Foreign currency translation adjustments

 

 

(2,493

)

 

 

(3,791

)

Retained earnings

 

 

646,038

 

 

 

624,151

 

Treasury stock, at cost; 15,205 and 14,893 shares held at July 4, 2025
   and January 3, 2025, respectively

 

 

(580,139

)

 

 

(545,047

)

Total stockholders’ equity

 

 

427,776

 

 

 

421,068

 

Total liabilities and stockholders’ equity

 

$

759,430

 

 

$

777,270

 

The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.

- 3 -


 

EXPONENT, INC.

Condensed Consolidated Statements of Income

For the Three and Six Months Ended July 4, 2025 and June 28, 2024

(unaudited)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

(In thousands, except per share data)

 

July 4,
2025

 

 

June 28,
2024

 

 

July 4,
2025

 

 

June 28,
2024

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Revenues before reimbursements

 

$

132,868

 

 

$

132,434

 

 

$

270,305

 

 

$

269,641

 

Reimbursements

 

 

9,094

 

 

 

8,102

 

 

 

17,164

 

 

 

15,828

 

Revenues

 

 

141,962

 

 

 

140,536

 

 

 

287,469

 

 

 

285,469

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Compensation and related expenses

 

 

97,474

 

 

 

79,466

 

 

 

173,377

 

 

 

169,793

 

Other operating expenses

 

 

12,072

 

 

 

11,185

 

 

 

24,167

 

 

 

21,716

 

Reimbursable expenses

 

 

9,094

 

 

 

8,102

 

 

 

17,164

 

 

 

15,828

 

General and administrative expenses

 

 

6,145

 

 

 

6,039

 

 

 

11,152

 

 

 

11,675

 

Total operating expenses

 

 

124,785

 

 

 

104,792

 

 

 

225,860

 

 

 

219,012

 

Operating income

 

 

17,177

 

 

 

35,744

 

 

 

61,609

 

 

 

66,457

 

Other income, net:

 

 

 

 

 

 

 

 

 

 

 

 

Interest income, net

 

 

2,344

 

 

 

2,231

 

 

 

5,058

 

 

 

4,857

 

Miscellaneous income, net

 

 

17,294

 

 

 

1,707

 

 

 

7,908

 

 

 

8,791

 

Total other income, net

 

 

19,638

 

 

 

3,938

 

 

 

12,966

 

 

 

13,648

 

Income before income taxes

 

 

36,815

 

 

 

39,682

 

 

 

74,575

 

 

 

80,105

 

Income taxes

 

 

10,262

 

 

 

10,455

 

 

 

21,372

 

 

 

20,736

 

Net income

 

$

26,553

 

 

$

29,227

 

 

$

53,203

 

 

$

59,369

 

Net income per share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

0.52

 

 

$

0.57

 

 

$

1.04

 

 

$

1.16

 

Diluted

 

$

0.52

 

 

$

0.57

 

 

$

1.03

 

 

$

1.15

 

Shares used in per share computations:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

51,185

 

 

 

51,111

 

 

 

51,234

 

 

 

51,059

 

Diluted

 

 

51,502

 

 

 

51,517

 

 

 

51,587

 

 

 

51,475

 

Cash dividends declared per common share

 

$

0.30

 

 

$

0.28

 

 

$

0.60

 

 

$

0.56

 

 

The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.

 

 

- 4 -


 

EXPONENT, INC.

Condensed Consolidated Statements of Comprehensive Income

For the Three and Six Months Ended July 4, 2025 and June 28, 2024

(unaudited)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

(In thousands)

 

July 4,
2025

 

 

June 28,
2024

 

 

July 4,
2025

 

 

June 28,
2024

 

Net income

 

$

26,553

 

 

$

29,227

 

 

$

53,203

 

 

$

59,369

 

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation
   adjustments, net of tax

 

 

352

 

 

 

14

 

 

 

1,298

 

 

 

(196

)

Comprehensive income

 

$

26,905

 

 

$

29,241

 

 

$

54,501

 

 

$

59,173

 

The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.

- 5 -


 

EXPONENT, INC

Condensed Consolidated Statements of Stockholders’ Equity

For the Three and Six Months Ended July 4, 2025 and June 28, 2024

(unaudited)

 

 

 

Three and Six Months Ended July 4, 2025

 

 

 

Common Stock

 

 

Additional
paid-in

 

 

Accumulated
other
comprehensive

 

 

Retained

 

 

Treasury Stock

 

 

 

 

(In thousands)

 

Shares

 

 

Amount

 

 

capital

 

 

loss

 

 

earnings

 

 

Shares

 

 

Amount

 

 

Total

 

Balance at January 3, 2025

 

 

65,707

 

 

$

66

 

 

$

345,689

 

 

$

(3,791

)

 

$

624,151

 

 

 

14,893

 

 

$

(545,047

)

 

$

421,068

 

Employee stock purchase plan

 

 

-

 

 

 

-

 

 

 

326

 

 

 

-

 

 

 

-

 

 

 

(5

)

 

 

58

 

 

 

384

 

Amortization of unrecognized stock-based
   compensation

 

 

-

 

 

 

-

 

 

 

5,028

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

5,028

 

Purchase of treasury shares

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

65

 

 

 

(5,000

)

 

 

(5,000

)

Foreign currency translation adjustments

 

 

-

 

 

 

-

 

 

 

-

 

 

 

946

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

946

 

Grant of restricted stock units to settle accrued
   bonus

 

 

-

 

 

 

-

 

 

 

12,179

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

12,179

 

Settlement of restricted stock units

 

 

-

 

 

 

-

 

 

 

(1,499

)

 

 

-

 

 

 

-

 

 

 

(95

)

 

 

(2,667

)

 

 

(4,166

)

Exercise of stock options

 

 

-

 

 

 

-

 

 

 

53

 

 

 

-

 

 

 

-

 

 

 

(5

)

 

 

47

 

 

 

100

 

Dividends and dividend equivalent rights

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(15,781

)

 

 

-

 

 

 

-

 

 

 

(15,781

)

Net income

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

26,650

 

 

 

-

 

 

 

-

 

 

 

26,650

 

Balance at April 4, 2025

 

 

65,707

 

 

$

66

 

 

$

361,776

 

 

$

(2,845

)

 

$

635,020

 

 

 

14,853

 

 

$

(552,609

)

 

$

441,408

 

Employee stock purchase plan

 

 

-

 

 

 

-

 

 

 

361

 

 

 

-

 

 

 

-

 

 

 

(6

)

 

 

66

 

 

 

427

 

Amortization of unrecognized stock-based
   compensation

 

 

-

 

 

 

-

 

 

 

2,251

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

2,251

 

Purchase of treasury shares

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

366

 

 

 

(27,680

)

 

 

(27,680

)

Foreign currency translation adjustments

 

 

-

 

 

 

-

 

 

 

-

 

 

 

352

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

352

 

Settlement of restricted stock units

 

 

-

 

 

 

-

 

 

 

(84

)

 

 

-

 

 

 

-

 

 

 

(8

)

 

 

84

 

 

 

-

 

Dividends and dividend equivalent rights

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(15,535

)

 

 

-

 

 

 

-

 

 

 

(15,535

)

Net income

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

26,553

 

 

 

-

 

 

 

-

 

 

 

26,553

 

Balance at July 4, 2025

 

 

65,707

 

 

$

66

 

 

$

364,304

 

 

$

(2,493

)

 

$

646,038

 

 

 

15,205

 

 

$

(580,139

)

 

$

427,776

 

 

 

 

The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.

 

- 6 -


 

EXPONENT, INC

Condensed Consolidated Statements of Stockholders’ Equity

For the Three and Six Months Ended July 4, 2025 and June 28, 2024

(unaudited)

 

 

 

Three and Six Months Ended June 28, 2024

 

 

 

Common Stock

 

 

Additional
paid-in

 

 

Accumulated
other
comprehensive

 

 

Retained

 

 

Treasury Stock

 

 

 

 

(In thousands)

 

Shares

 

 

Amount

 

 

capital

 

 

income (loss)

 

 

earnings

 

 

Shares

 

 

Amount

 

 

Total

 

Balance at December 29, 2023

 

 

65,707

 

 

$

66

 

 

$

321,448

 

 

$

(2,977

)

 

$

574,082

 

 

 

15,134

 

 

$

(536,534

)

 

$

356,085

 

Employee stock purchase plan

 

 

-

 

 

 

-

 

 

 

450

 

 

 

-

 

 

 

-

 

 

 

(7

)

 

 

68

 

 

 

518

 

Amortization of unrecognized stock-based
   compensation

 

 

-

 

 

 

-

 

 

 

4,026

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

4,026

 

Purchase of treasury shares

 

 

 

 

 

 

 

 

-

 

 

 

-

 

 

 

 

 

 

71

 

 

 

(5,466

)

 

 

(5,466

)

Foreign currency translation adjustments

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(210

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(210

)

Grant of restricted stock units to settle accrued bonus

 

 

-

 

 

 

-

 

 

 

10,846

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

10,846

 

Settlement of restricted stock units

 

 

-

 

 

 

-

 

 

 

(1,797

)

 

 

-

 

 

 

(720

)

 

 

(159

)

 

 

(4,279

)

 

 

(6,796

)

Exercise of stock options

 

 

-

 

 

 

-

 

 

 

41

 

 

 

-

 

 

 

-

 

 

 

(6

)

 

 

59

 

 

 

100

 

Dividends and dividend equivalent rights

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(14,934

)

 

 

-

 

 

 

-

 

 

 

(14,934

)

Net income

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

30,142

 

 

 

-

 

 

 

-

 

 

 

30,142

 

Balance at March 29, 2024

 

 

65,707

 

 

$

66

 

 

$

335,014

 

 

$

(3,187

)

 

$

588,570

 

 

 

15,033

 

 

$

(546,152

)

 

$

374,311

 

Employee stock purchase plan

 

 

-

 

 

 

-

 

 

 

392

 

 

 

-

 

 

 

-

 

 

 

(5

)

 

 

48

 

 

 

440

 

Amortization of unrecognized stock-based
   compensation

 

 

-

 

 

 

-

 

 

 

2,495

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

2,495

 

Purchase of treasury shares

 

 

 

 

 

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

3

 

 

 

(244

)

 

 

(244

)

Foreign currency translation adjustments

 

 

-

 

 

 

-

 

 

 

-

 

 

 

14

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

14

 

Settlement of restricted stock units

 

 

-

 

 

 

-

 

 

 

(78

)

 

 

-

 

 

 

-

 

 

 

(7

)

 

 

78

 

 

 

-

 

Exercise of stock options

 

 

 

 

 

 

 

 

911

 

 

 

-

 

 

 

-

 

 

 

(48

)

 

 

483

 

 

 

1,394

 

Dividends and dividend equivalent rights

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(14,424

)

 

 

-

 

 

 

-

 

 

 

(14,424

)

Net income

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

29,227

 

 

 

-

 

 

 

-

 

 

 

29,227

 

Balance at June 28, 2024

 

 

65,707

 

 

$

66

 

 

$

338,734

 

 

$

(3,173

)

 

$

603,373

 

 

 

14,976

 

 

$

(545,787

)

 

$

393,213

 

 

The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.

- 7 -


 

EXPONENT, INC.

Condensed Consolidated Statements of Cash Flows

For the Six Months Ended July 4, 2025 and June 28, 2024

(unaudited)

 

 

 

Six Months Ended

 

(In thousands)

 

July 4,
2025

 

 

June 28,
2024

 

Cash flows from operating activities:

 

 

 

 

 

 

Net income

 

$

53,203

 

 

$

59,369

 

Adjustments to reconcile net income to net cash provided by
   operating activities:

 

 

 

 

 

 

Depreciation and amortization of property, equipment and
   leasehold improvements

 

 

5,012

 

 

 

4,810

 

Provision for contract losses and doubtful accounts

 

 

586

 

 

 

2,359

 

Stock-based compensation

 

 

13,426

 

 

 

12,917

 

Deferred income tax provision

 

 

(3,094

)

 

 

2,264

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

(10,191

)

 

 

(869

)

Prepaid expenses and other current assets

 

 

7,135

 

 

 

1,769

 

Change in operating leases

 

 

1,756

 

 

 

79

 

Accounts payable and accrued liabilities

 

 

4,153

 

 

 

2,555

 

Accrued payroll and employee benefits

 

 

(23,774

)

 

 

(18,548

)

Deferred revenues

 

 

(4,716

)

 

 

(7,934

)

Net cash provided by operating activities

 

 

43,496

 

 

 

58,771

 

Cash flows from investing activities:

 

 

 

 

 

 

Capital expenditures

 

 

(4,028

)

 

 

(2,628

)

Net cash used in investing activities

 

 

(4,028

)

 

 

(2,628

)

Cash flows from financing activities:

 

 

 

 

 

 

Payroll taxes for restricted stock units

 

 

(4,166

)

 

 

(6,796

)

Repurchase of common stock

 

 

(32,680

)

 

 

(5,710

)

Exercise of stock-based payment awards

 

 

911

 

 

 

2,453

 

Dividends and dividend equivalents rights

 

 

(31,582

)

 

 

(29,776

)

Net cash used in financing activities

 

 

(67,517

)

 

 

(39,829

)

Effect of foreign currency exchange rates on cash and cash equivalents

 

 

949

 

 

 

(202

)

Net change in cash and cash equivalents

 

 

(27,100

)

 

 

16,112

 

Cash and cash equivalents at beginning of period

 

 

258,901

 

 

 

187,150

 

Cash and cash equivalents at end of period

 

$

231,801

 

 

$

203,262

 

The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.

- 8 -


 

EXPONENT, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1: Basis of Presentation

Exponent, Inc. (referred to as the “Company” or “Exponent”) is an engineering and scientific consulting firm that provides solutions to complex problems. The Company operates on a 52-53 week fiscal year ending on the Friday closest to the last day of December.

The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission. Accordingly, they do not contain all the information and notes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments which are necessary for the fair presentation of the condensed consolidated financial statements have been included and all such adjustments are of a normal and recurring nature. The operating results for the three and six months ended July 4, 2025 are not necessarily representative of the results of future quarterly or annual periods. The following information should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended January 3, 2025, which was filed with the U.S. Securities and Exchange Commission on February 28, 2025 and amended on April 18, 2025.

The unaudited condensed consolidated financial statements include the accounts of Exponent and its subsidiaries, which are all wholly owned. All intercompany accounts and transactions have been eliminated in consolidation.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Items subject to such estimates and assumptions include accounting for revenue recognition and estimating the allowance for contract losses and doubtful accounts. Actual results could differ from those estimates.

Recent Accounting Pronouncement Not Yet Adopted

In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update (“ASU”) No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. The standard is effective for annual reporting periods beginning after December 15, 2024. The Company is evaluating the effect that this standard may have on its consolidated financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (subtopic 220-40), which requires disclosure of disaggregation of certain relevant expenses included in the statements of operations on an annual and interim basis. ASU 2024-03 will be effective for our annual periods beginning January 1, 2027 and interim periods beginning January 1, 2028. The amendments must be applied retrospectively, and early adoption is permitted. The Company is evaluating the effect that this standard may have on its consolidated financial statements and related disclosures.

Note 2: Revenue Recognition

Substantially all of the Company’s engagements are performed under time and materials or fixed-price arrangements. For time and materials contracts, the Company utilizes the practical expedient under Accounting Standards Codification 606 – Revenue from Contracts with Customers, which states if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity’s performance completed to date (for example, a service contract in which an entity bills a fixed amount for each hour of service provided) then the entity may recognize revenue in the amount to which the entity has a right to invoice.

- 9 -


 

The following table discloses the percent of the Company’s revenue generated from time and materials contracts:

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 4,
2025

 

 

June 28,
2024

 

 

July 4,
2025

 

 

June 28,
2024

 

Engineering & other scientific

 

 

65

%

 

 

62

%

 

 

66

%

 

 

64

%

Environmental and health

 

 

15

%

 

 

15

%

 

 

14

%

 

 

16

%

Total time and materials revenues

 

 

80

%

 

 

77

%

 

 

80

%

 

 

80

%

For fixed-price contracts, the Company recognizes revenue over time because of the continuous transfer of control to the customer. The customer typically controls the work in process as evidenced either by contractual termination clauses or by the Company’s rights to payment for work performed to date to deliver services that do not have an alternative use to the Company. Revenue for fixed-price contracts is recognized based on the relationship of incurred labor hours at standard rates to the Company’s estimate of the total labor hours at standard rates it expects to incur over the term of the contract. The Company believes this methodology achieves a reliable measure of the revenue from the consulting services it provides to its customers under fixed-price contracts given the nature of the consulting services the Company provides.

The following table discloses the percent of the Company’s revenue generated from fixed price contracts:

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 4,
2025

 

 

June 28,
2024

 

 

July 4,
2025

 

 

June 28,
2024

 

Engineering & other scientific

 

 

19

%

 

 

22

%

 

 

19

%

 

 

19

%

Environmental and health

 

 

1

%

 

 

1

%

 

 

1

%

 

 

1

%

Total fixed price revenues

 

 

20

%

 

 

23

%

 

 

20

%

 

 

20

%

Deferred revenues represent amounts billed to clients in advance of services provided. During the second quarter of 2025, $6,658,000 of revenues were recognized that were included in the deferred revenue balance at April 4, 2025. During the first six months of 2025, $8,326,000 of revenues were recognized that were included in the deferred revenue balance at January 3, 2025.

Reimbursements, including those related to travel and other out-of-pocket expenses, and other similar third- party costs such as the cost of materials and certain subcontracts, are included in revenues, and an equivalent amount of reimbursable expenses are included in operating expenses. Any mark-up on reimbursable expenses is included in revenues before reimbursements. The Company reports revenues net of subcontractor fees for certain subcontracts where the Company has determined that it is acting as an agent because its performance obligation is to arrange for the provision of goods or services by another party. The total amount of subcontractor fees not included in revenues because the Company was acting as an agent were $3,178,000 and $3,787,000 during the second quarter of 2025 and 2024, respectively, and $6,682,000 and $6,533,000 during the first six months of 2025 and 2024, respectively.

- 10 -


 

Note 3: Fair Value Measurements

The Company measures certain financial assets and liabilities at fair value on a recurring basis, including money market securities, trading fixed income and equity securities held in its deferred compensation plan and the liability associated with its deferred compensation plan. There were no transfers between fair value measurement levels during the three and six months ended July 4, 2025 and June 28, 2024. Any transfers between fair value measurement levels would be recorded on the actual date of the event or change in circumstances that caused the transfer. The fair value of these certain financial assets and liabilities was determined using the following inputs at July 4, 2025:

 

 

 

Fair Value Measurements at Reporting Date Using

 

(In thousands)

 

Total

 

 

Quoted Prices in
Active Markets
for Identical
Assets
(Level 1)

 

 

Significant Other
Observable Inputs
(Level 2)

 

 

Significant
Unobservable
Inputs
(Level 3)

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Money market securities (1)

 

$

58,979

 

 

$

58,979

 

 

$

-

 

 

$

-

 

Fixed income trading securities held in deferred
   compensation plan
(2)

 

 

43,899

 

 

 

43,899

 

 

 

-

 

 

 

-

 

Equity trading securities held in deferred compensation
   plan
(2)

 

 

88,417

 

 

 

88,417

 

 

 

-

 

 

 

-

 

Total

 

$

191,295

 

 

$

191,295

 

 

$

-

 

 

$

-

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Deferred compensation plan (3)

 

 

134,941

 

 

 

134,941

 

 

 

-

 

 

 

-

 

Total

 

$

134,941

 

 

$

134,941

 

 

$

-

 

 

$

-

 

 

(1)
Included in cash and cash equivalents on the Company’s unaudited condensed consolidated balance sheet.
(2)
Included in prepaid expenses and other current assets and deferred compensation plan assets on the Company’s unaudited condensed consolidated balance sheet.
(3)
Included in accrued payroll and employee benefits and deferred compensation plan liabilities on the Company’s unaudited condensed consolidated balance sheet.

- 11 -


 

The fair value of these certain financial assets and liabilities was determined using the following inputs at January 3, 2025:

 

 

 

Fair Value Measurements at Reporting Date Using

 

(In thousands)

 

Total

 

 

Quoted Prices in
Active Markets
for Identical
Assets
(Level 1)

 

 

Significant Other
Observable Inputs
(Level 2)

 

 

Significant
Unobservable
Inputs
(Level 3)

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Money market securities (1)

 

$

57,549

 

 

$

57,549

 

 

$

-

 

 

$

-

 

Fixed income trading securities held in deferred
   compensation plan
(2)

 

 

42,291

 

 

 

42,291

 

 

 

-

 

 

 

-

 

Equity trading securities held in deferred compensation
   plan
(2)

 

 

85,546

 

 

 

85,546

 

 

 

-

 

 

 

-

 

Total

 

$

185,386

 

 

$

185,386

 

 

$

-

 

 

$

-

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Deferred compensation plan (3)

 

 

127,622

 

 

 

127,622

 

 

 

-

 

 

 

-

 

Total

 

$

127,622

 

 

$

127,622

 

 

$

-

 

 

$

-

 

 

(1)
Included in cash and cash equivalents on the Company’s unaudited condensed consolidated balance sheet.
(2)
Included in prepaid expenses and other current assets and deferred compensation plan assets on the Company’s unaudited condensed consolidated balance sheet.
(3)
Included in accrued payroll and employee benefits and deferred compensation plan liabilities on the Company’s unaudited condensed consolidated balance sheet.

Money market securities as of July 4, 2025 and January 3, 2025 represent obligations of the United States Treasury. Fixed income and equity trading securities represent mutual funds held in the Company’s deferred compensation plan. See Note 6 for additional information about the Company’s deferred compensation plan.

Cash and cash equivalents consisted of the following as of July 4, 2025:

 

 

 

 

 

 

Gross

 

 

Gross

 

 

 

 

 

 

Amortized

 

 

Unrealized

 

 

Unrealized

 

 

Estimated

 

(In thousands)

 

Cost

 

 

Gains

 

 

Losses

 

 

Fair Value

 

Classified as current assets:

 

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$

172,822

 

 

$

-

 

 

$

-

 

 

$

172,822

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market securities

 

 

58,979

 

 

 

-

 

 

 

-

 

 

 

58,979

 

Total cash equivalents

 

 

58,979

 

 

 

-

 

 

 

-

 

 

 

58,979

 

Total cash and cash equivalents

 

$

231,801

 

 

$

-

 

 

$

-

 

 

$

231,801

 

 

Cash and cash equivalents consisted of the following as of January 3, 2025:

 

 

 

 

 

 

Gross

 

 

Gross

 

 

 

 

 

 

Amortized

 

 

Unrealized

 

 

Unrealized

 

 

Estimated

 

(In thousands)

 

Cost

 

 

Gains

 

 

Losses

 

 

Fair Value

 

Classified as current assets:

 

 

 

 

 

 

 

 

 

 

 

 

Cash

 

$

201,352

 

 

$

-

 

 

$

-

 

 

$

201,352

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market securities

 

 

57,549

 

 

 

-

 

 

 

-

 

 

 

57,549

 

Total cash equivalents

 

 

57,549

 

 

 

-

 

 

 

-

 

 

 

57,549

 

Total cash and cash equivalents

 

$

258,901

 

 

$

-

 

 

$

-

 

 

$

258,901

 

 

- 12 -


 

 

At July 4, 2025 and January 3, 2025, the Company did not have any assets or liabilities valued using significant unobservable inputs.

The following financial instruments are not measured at fair value on the Company's unaudited condensed consolidated balance sheet at July 4, 2025 and January 3, 2025, but require disclosure of their fair values: accounts receivable, other assets and accounts payable. Due to their short-term nature, the estimated fair value of such instruments at July 4, 2025 and January 3, 2025 approximates their carrying value as reported on the Company’s unaudited condensed consolidated balance sheet.

Note 4: Net Income Per Share

Basic per share amounts are computed using the weighted-average number of shares of common stock outstanding during the period. Diluted per share amounts are calculated using the weighted-average number of shares of common stock outstanding during the period and, when dilutive, the weighted-average number of potential shares of common stock from the issuance of common stock to satisfy outstanding restricted stock units and the exercise of outstanding options to purchase common stock using the treasury stock method.

The following schedule reconciles the shares used to calculate basic and diluted net income per share:

 

 

 

Three Months Ended

 

 

Six Months Ended

 

(In thousands)

 

July 4,
2025

 

 

June 28,
2024

 

 

July 4,
2025

 

 

June 28,
2024

 

Shares used in basic per share computation

 

 

51,185

 

 

 

51,111

 

 

 

51,234

 

 

 

51,059

 

Effect of dilutive common stock options
   outstanding

 

 

82

 

 

 

174

 

 

 

93

 

 

 

169

 

Effect of dilutive restricted stock units
   outstanding

 

 

235

 

 

 

232

 

 

 

260

 

 

 

247

 

Shares used in diluted per share
   computation

 

 

51,502

 

 

 

51,517

 

 

 

51,587

 

 

 

51,475

 

Common stock options to purchase 175,833 shares and 63,333 shares were excluded from the diluted per share calculation for the three months ended July 4, 2025 and June 28, 2024, respectively, due to their anti-dilutive effect. Common stock options to purchase 135,833 shares and 100,833 shares were excluded from the diluted per share calculation for the six months ended July 4, 2025 and June 28, 2024, respectively, due to their anti-dilutive effect.

Note 5: Stock-Based Compensation

Restricted Stock Units

Restricted stock unit grants are designed to attract and retain employees, and to better align employee interests with those of the Company’s stockholders. For a select group of employees, up to 40% of their annual bonus is settled with fully vested restricted stock unit awards. Under these fully vested restricted stock unit awards, the holder of each award has the right to receive one share of the Company’s common stock for each fully vested restricted stock unit four years from the date of grant. Each individual who receives a fully vested restricted stock unit award is also granted a matching number of unvested restricted stock unit awards. Unvested restricted stock unit awards are also granted for select new hires and promotions. These unvested restricted stock unit awards generally cliff vest four years from the date of grant, at which time the holder of each award will have the right to receive one share of the Company’s common stock for each restricted stock unit award provided the holder of each award has met certain employment conditions. In the case of retirement at 59½ years or older, all unvested restricted stock unit awards will continue to vest, provided that the holder of each award does all consulting work through the Company and does not become an employee for a past or present client, beneficial party or competitor of the Company.

The value of these restricted stock unit awards is determined based on the market price of the Company’s common stock on the date of grant. The value of fully vested restricted stock unit awards issued is recorded as a reduction to accrued bonuses. The portion of bonus expense that the Company expects to settle with fully vested

- 13 -


 

restricted stock unit awards is recorded as stock-based compensation during the period the bonus is earned. The Company recorded stock-based compensation expense associated with accrued bonus awards of $2,995,000 and $3,082,000 during the three months ended July 4, 2025 and June 28, 2024, respectively. For the six months ended July 4, 2025 and June 28, 2024, the Company recorded stock-based compensation expense associated with accrued bonus awards of $6,147,000 and $6,396,000, respectively. The value of the unvested restricted stock unit awards granted is recognized on a straight-line basis over the shorter of the four-year vesting period or the period between the grant date and the date the award recipient turns 59½. If the award recipient is 59½ years or older on the date of grant, the value of the entire award is expensed upon grant. The Company recorded stock-based compensation expense associated with the unvested restricted stock unit awards of $2,076,000 and $2,127,000 during the three months ended July 4, 2025 and June 28, 2024, respectively. The Company recorded stock-based compensation expense associated with the unvested restricted stock unit awards of $6,316,000 and $5,834,000 during the six months ended July 4, 2025 and June 28, 2024, respectively.

Stock Options

Stock options are granted for terms of ten years and generally vest 25% per year over a four-year period from the grant date. Unvested stock option awards will continue to vest in the case of retirement at 59½ years or older, provided that the holder of each award does all consulting work through the Company and does not become an employee for a past or present client, beneficial party or competitor of the Company. The value of the unvested stock option awards granted is recognized on a straight-line basis over the shorter of the four-year vesting period or the period between the grant date and the date the award recipient turns 59½. If the award recipient is 59½ years or older on the date of grant, the value of the entire award is expensed upon grant. The Company recorded stock-based compensation expense associated with stock option grants of $175,000 and $368,000 during the three months ended July 4, 2025 and June 28, 2024, respectively. The Company recorded stock-based compensation expense associated with stock option grants of $963,000 and $687,000 during the six months ended July 4, 2025 and June 28, 2024, respectively.

The Company uses the Black-Scholes option-pricing model to determine the fair value of options granted. The determination of the fair value of stock option awards on the date of grant using an option-pricing model is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables. These variables include expected stock price volatility over the term of the award, actual and projected employee stock option exercise behaviors, the risk-free interest rate and expected dividends.

The Company used historical exercise, forfeiture, and post-vesting expiration data to estimate the expected term of options granted. The historical volatility of the Company’s common stock over a period of time equal to the expected term of the options granted was used to estimate expected volatility. The risk-free interest rate used in the option-pricing model was based on United States Treasury zero-coupon issues with remaining terms similar to the expected term of the options. The dividend yield assumption considers the expectation of continued declaration of dividends, offset by option holders’ dividend equivalent rights.

The Company accounts for forfeitures of stock-based awards when they occur. All stock-based payment awards are recognized on a straight-line basis over the requisite service periods of the awards.

Note 6: Deferred Compensation Plans

The Company maintains nonqualified deferred compensation plans for the benefit of a select group of highly compensated employees. Under these plans, participants may elect to defer up to 100% of their compensation. Company assets that are earmarked to pay benefits under the plans are held in a rabbi trust and are subject to the claims of the Company’s creditors. As of July 4, 2025 and January 3, 2025, the invested amounts under the plans totaled $132,315,000 and $127,837,000, respectively, and are recorded in prepaid expenses and other current assets and deferred compensation plan assets on the Company’s unaudited condensed consolidated balance sheet. These assets are classified as trading securities and are recorded at fair value with changes recorded as adjustments to miscellaneous income, net.

As of July 4, 2025 and January 3, 2025, vested amounts due under the plans totaled $134,941,000 and $127,622,000, respectively, and are recorded within accrued payroll and employee benefits and deferred compensation plan liabilities on the Company’s unaudited condensed consolidated balance sheets. Changes in the liability are

- 14 -


 

recorded as adjustments to compensation expense. During the three months ended July 4, 2025, the Company recognized additional compensation expense of $16,963,000 as a result of changes in the market value of the trust assets with the same amount being recorded as a gain in miscellaneous income, net. During the three months ended June 28, 2024, the Company recognized additional compensation expense of $875,000 as a result of changes in the market value of the trust assets with the same amount being recorded as a gain in miscellaneous income, net. During the six months ended July 4, 2025, the Company recognized additional compensation expense of $7,627,000 as a result of changes in the market value of the trust assets with the same amount being recorded as a gain in miscellaneous income, net. During the six months ended June 28, 2024, the Company recognized additional compensation expense of $7,144,000 as a result of changes in the market value of the trust assets with the same amount being recorded as a gain in miscellaneous income, net.

Note 7: Supplemental Cash Flow Information

The following is supplemental disclosure of cash flow information:

 

 

 

Six Months Ended

 

(In thousands)

 

July 4,
2025

 

 

June 28,
2024

 

Cash paid during period:

 

 

 

 

 

 

Income taxes

 

$

20,330

 

 

$

18,490

 

Non-cash investing and financing activities:

 

 

 

 

 

 

Vested stock unit awards issued to settle accrued bonuses

 

$

12,179

 

 

$

10,846

 

Accrual for capital expenditures

 

$

189

 

 

$

25

 

Right-of-use asset obtained in exchange for operating lease obligations

 

$

685

 

 

$

50,657

 

 

Note 8: Accounts Receivable, Net

At July 4, 2025 and January 3, 2025, accounts receivable, net, was comprised of the following:

 

 

 

July 4,

 

 

January 3,

 

(In thousands)

 

2025

 

 

2025

 

Billed accounts receivable

 

$

117,447

 

 

$

117,503

 

Unbilled accounts receivable

 

 

59,745

 

 

 

50,045

 

Allowance for contract losses and doubtful accounts

 

 

(6,180

)

 

 

(6,141

)

Total accounts receivable, net

 

$

171,012

 

 

$

161,407

 

 

The Company maintains allowances for estimated losses over the remaining contractual life of its receivables resulting from the inability of customers to meet their financial obligations or for disputes that affect the Company’s ability to fully collect amounts due. In circumstances where the Company is aware of a specific customer’s inability to meet its financial obligations or aware of a dispute with a specific customer, a specific allowance is recorded to reduce the net recognized receivable to the amount the Company reasonably believes will be collected. For all other customers the Company recognizes allowances for doubtful accounts based upon historical write-offs, customer concentration, customer creditworthiness, current economic conditions, aging of amounts due and future expectations.

 

A reconciliation of the beginning and ending amount of the allowance for contract losses and doubtful accounts is as follows:

 

(In thousands)

 

 

 

Balance at January 3, 2025

 

$

6,141

 

Provision for contract losses and doubtful accounts

 

 

586

 

Write-offs

 

 

(547

)

Balance at July 4, 2025

 

$

6,180

 

 

- 15 -


 

Note 9: Segment Reporting

The Company has two reportable operating segments based on two primary areas of service. The Engineering and other scientific segment is a broad service group providing technical consulting in different practices primarily in engineering. The Environmental and health segment provides services in the areas of environmental, epidemiology and health risk analysis. This segment provides a wide range of consulting services relating to environmental hazards and risks and the impact on both human health and the environment. Our Chief Executive Officer, the chief operating decision maker, reviews revenues and operating income for each of our reportable segments, but does not review total assets in evaluating segment performance and capital allocation.

Segment information for the three and six months ended July 4, 2025 and June 28, 2024 follows:

Revenues

 

 

 

Three Months Ended

 

 

Six Months Ended

 

(In thousands)

 

July 4,
2025

 

 

June 28,
2024

 

 

July 4,
2025

 

 

June 28,
2024

 

Engineering and other scientific

 

$

120,980

 

 

$

118,477

 

 

$

243,115

 

 

$

239,948

 

Environmental and health

 

 

20,982

 

 

 

22,059

 

 

 

44,354

 

 

 

45,521

 

Total revenues

 

$

141,962

 

 

$

140,536

 

 

$

287,469

 

 

$

285,469

 

 

Compensation and related expenses

 

 

 

Three Months Ended

 

 

Six Months Ended

 

(In thousands)

 

July 4,
2025

 

 

June 28,
2024

 

 

July 4,
2025

 

 

June 28,
2024

 

Engineering and other scientific

 

$

56,914

 

 

$

56,802

 

 

$

114,162

 

 

$

114,537

 

Environmental and health

 

 

11,740

 

 

 

12,041

 

 

 

24,188

 

 

 

24,357

 

Total segment compensation and related expenses

 

 

68,654

 

 

 

68,843

 

 

 

138,350

 

 

 

138,894

 

Corporate compensation and related expenses

 

 

28,820

 

 

 

10,623

 

 

 

35,027

 

 

 

30,899

 

Total compensation and related expenses

 

$

97,474

 

 

$

79,466

 

 

$

173,377

 

 

$

169,793

 

 

Operating Income

 

 

 

Three Months Ended

 

 

Six Months Ended

 

(In thousands)

 

July 4,
2025

 

 

June 28,
2024

 

 

July 4,
2025

 

 

June 28,
2024

 

Engineering and other scientific

 

$

42,942

 

 

$

43,765

 

 

$

88,055

 

 

$

92,396

 

Environmental and health

 

 

7,020

 

 

 

7,259

 

 

 

15,718

 

 

 

15,495

 

Total segment operating income

 

 

49,962

 

 

 

51,024

 

 

 

103,773

 

 

 

107,891

 

Corporate operating expense

 

 

(32,785

)

 

 

(15,280

)

 

 

(42,164

)

 

 

(41,434

)

Total operating income

 

$

17,177

 

 

$

35,744

 

 

$

61,609

 

 

$

66,457

 

 

Certain operating expenses are excluded from the Company’s measure of segment operating income. These expenses include costs associated with its human resources, legal, finance, information technology, and business development groups; the deferred compensation expense/benefit due to the change in value of assets associated with its deferred compensation plan; stock-based compensation associated with restricted stock unit and stock option awards; and the change in its allowance for contract losses and doubtful accounts.

- 16 -


 

Capital Expenditures

 

 

 

Three Months Ended

 

 

Six Months Ended

 

(In thousands)

 

July 4,
2025

 

 

June 28,
2024

 

 

July 4,
2025

 

 

June 28,
2024

 

Engineering and other scientific

 

$

306

 

 

$

465

 

 

$

781

 

 

$

882

 

Environmental and health

 

 

39

 

 

 

45

 

 

 

101

 

 

 

74

 

Total segment capital expenditures

 

 

345

 

 

 

510

 

 

 

882

 

 

 

956

 

Corporate capital expenditures

 

 

2,045

 

 

 

497

 

 

 

2,760

 

 

 

1,560

 

Total capital expenditures

 

$

2,390

 

 

$

1,007

 

 

$

3,642

 

 

$

2,516

 

 

Certain capital expenditures associated with the Company’s corporate cost centers and the related depreciation are excluded from the Company’s segment information.

 

Depreciation and Amortization

 

 

 

Three Months Ended

 

 

Six Months Ended

 

(In thousands)

 

July 4,
2025

 

 

June 28,
2024

 

 

July 4,
2025

 

 

June 28,
2024

 

Engineering and other scientific

 

$

1,836

 

 

$

1,765

 

 

$

3,662

 

 

$

3,393

 

Environmental and health

 

 

49

 

 

 

54

 

 

 

96

 

 

 

103

 

Total segment depreciation and
   amortization

 

 

1,885

 

 

 

1,819

 

 

 

3,758

 

 

 

3,496

 

Corporate depreciation and amortization

 

 

635

 

 

 

667

 

 

 

1,254

 

 

 

1,314

 

Total depreciation and amortization

 

$

2,520

 

 

$

2,486

 

 

$

5,012

 

 

$

4,810

 

 

No single client comprised more than 10% of the Company’s revenues during the three and six months ended July 4, 2025 and June 28, 2024.

Note 10: Leases

The Company determines if an arrangement is a lease at the inception of the arrangement. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and long-term operating lease liabilities in the Company’s condensed consolidated balance sheet. The Company does not have any finance leases as of July 4, 2025.

ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate, based on the information available at commencement date, in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The amortization of operating lease ROU assets and the change in operating lease liabilities is disclosed as a single line item in the condensed consolidated statements of cash flows.

The Company leases office, laboratory, and storage space in 13 states and the District of Columbia, as well as in China, Hong Kong, Singapore, Switzerland, and the United Kingdom. Leases for these office, laboratory, and storage facilities have terms generally ranging between one and ten years. Some of these leases include options to extend or terminate the lease, none of which are currently included in the lease term as the Company has determined that exercise of these options is not reasonably certain.

- 17 -


 

The Company has a Test and Engineering Center on 147 acres of land in Phoenix, Arizona. The Company leases this land from the State of Arizona under an agreement that expires in January of 2043 that includes an option to renew for one fifteen-year period.

The Company’s equipment leases are included in the ROU asset and liability balances, but are not material.

The Company leases excess space in its Silicon Valley and Natick facilities. Rental income of $285,000 and $927,000 was included in other income for the three months ended July 4, 2025 and June 28, 2024, respectively. Rental income of $476,000 and $1,769,000 was included in other income for the six months ended June 28, 2024 and June 28, 2024, respectively.

The components of lease expense included in other operating expenses on the condensed consolidated statements of income were as follows:

 

 

 

Three Months Ended

 

 

Six Months Ended

 

(In thousands)

 

July 4,
2025

 

 

June 28,
2024

 

 

July 4,
2025

 

 

June 28,
2024

 

Operating lease cost

 

$

2,896

 

 

$

2,392

 

 

$

6,108

 

 

$

4,507

 

Variable lease cost

 

 

414

 

 

 

385

 

 

 

717

 

 

 

748

 

Short-term lease cost

 

 

381

 

 

 

343

 

 

 

737

 

 

 

650

 

 

Supplemental cash flow information related to operating leases was as follows:

 

 

 

Three Months Ended

 

 

Six Months Ended

 

(In thousands)

 

July 4, 2025

 

 

June 28, 2024

 

 

July 4, 2025

 

 

June 28, 2024

 

Cash paid for amounts included in the
   measurement of operating lease
   liabilities

 

$

1,678

 

 

$

1,804

 

 

$

4,280

 

 

$

4,348

 

 

Supplemental balance sheet information related to operating leases was as follows:

 

 

 

July 4,
2025

 

June 28, 2024

Weighted Average Remaining Lease Term

 

13.5 years

 

14.5 years

Weighted Average Discount Rate

 

6.3%

 

6.4%

 

Maturities of operating lease liabilities as of July 4, 2025:

 

 

 

Operating

 

(In thousands)

 

Leases

 

2025 (excluding the six months ended July 4, 2025)

 

$

3,665.00

 

2026

 

 

8,149

 

2027

 

 

6,817

 

2028

 

 

9,849

 

2029

 

 

9,467

 

Thereafter

 

 

89,052

 

Total lease payments

 

 

126,999

 

Less imputed interest

 

 

(46,676

)

Total lease liability

 

$

80,323

 

 

Note 11: Contingencies

The Company is a party to various legal actions from time to time and may be contingently liable in connection with claims and contracts arising in the normal course of business, the outcome of which the Company believes, after consultation with legal counsel, will not have a material adverse effect on its financial condition, results

- 18 -


 

of operations or liquidity. However, due to the risks and uncertainties inherent in legal proceedings, actual results could differ from current expected results. All legal costs associated with litigation are expensed as incurred.

Note 12: Subsequent Events

On July 31, 2025, the Company’s Board of Directors announced a cash dividend of $0.30 per share of the Company’s common stock, payable September 19, 2025, to stockholders of record as of September 5, 2025.

- 19 -


 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto included herein and with our audited consolidated financial statements and notes thereto for the fiscal year ended January 3, 2025, which are contained in our fiscal 2024 Annual Report on Form 10-K, which was filed with the U.S. Securities and Exchange Commission on February 28, 2025 and amended on April 18, 2025 (our “2024 Annual Report”).

Forward-Looking Statements

 

This Quarterly Report on Form 10-Q contains certain “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995, and the rules promulgated pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended) that are based on the beliefs of our management, as well as assumptions made by and information currently available to our management. Such forward-looking statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. When used in this document, the words “intend,” “anticipate,” “believe,” “estimate,” “expect” and similar expressions, as they relate to us or our management, identify such forward-looking statements. Such statements reflect the current views of us or our management with respect to future events and are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, our actual results, performance, or achievements could differ materially from those expressed in, or implied by, any such forward-looking statements. Factors that could cause or contribute to such material differences include the possibility that the demand for our services may decline as a result of changes in general and industry specific economic conditions, the timing of engagements for our services, the effects of competitive services and pricing, the absence of backlog related to our business, our ability to attract and retain key employees, the effect of tort reform and government regulation on our business and liabilities resulting from claims made against us. Additional risks and uncertainties are discussed in our 2024 Annual Report under the heading “Risk Factors” and elsewhere in this report. The inclusion of such forward-looking information should not be regarded as a representation by the us or any other person that the future events, plans, or expectations we contemplated will be achieved. Due to such uncertainties and risks, you are warned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. We do not intend to release publicly any updates or revisions to any such forward-looking statements.

Business Overview

Exponent, Inc. is an engineering and scientific consulting firm providing solutions to complex problems. Our interdisciplinary organization of scientists, physicians, engineers, and business consultants draws from more than 90 technical disciplines to solve the most pressing and complicated challenges facing stakeholders today. The firm leverages over 50 years of experience in analyzing accidents and failures to advise clients as they innovate their technologically complex products and processes, ensure the safety and health of their users, and address the challenges of sustainability.

CRITICAL ACCOUNTING ESTIMATES

There have been no significant changes in our critical accounting estimates during the six months ended July 4, 2025, as compared to the critical accounting estimates disclosed in Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our 2024 Annual Report.

RESULTS OF CONSOLIDATED OPERATIONS

Executive Summary

Revenues for the second quarter of 2025 increased 1% to $141,962,000 as compared to $140,536,000 during the same period last year. Revenues before reimbursements for the second quarter of 2025 increased slightly to $132,868,000 as compared to $132,434,000 during the same period last year. Our failure analysis expertise drove increased dispute-related activities in the construction, automotive and medical device sectors. Proactive engagements were led by risk management work in the utilities sector, offset by softer demand in chemical regulatory work.

- 20 -


 

Net income decreased 9% to $26,553,000 during the second quarter of 2025 as compared to $29,227,000 during the same period last year. Diluted earnings per share decreased to $0.52 per share during the second quarter of 2025 as compared to $0.57 in the same period last year. The decrease in profitability was due to an increase in compensation expense associated with our annual salary adjustments, an increase in other operating expenses associated with the extension of our land lease with the State of Arizona and a decrease in the tax benefit associated with stock-based awards. During the second quarter of 2025, the tax impact associated with share-based awards was immaterial as compared to a tax benefit of $726,000 recognized during the same period last year.

We remain focused on building our world-class engineering and scientific team to position us at the forefront of innovation and meet the ever-changing needs of our clients and the market. We also remain focused on capitalizing on emerging growth areas, managing other operating expenses, generating cash from operations, maintaining a strong balance sheet and undertaking activities such as share repurchases and dividends to enhance stockholder value.

Overview of the Three Months Ended July 4, 2025

During the second quarter of 2025, billable hours decreased 6% to 359,000 as compared to 381,000 during the same period last year. Our utilization decreased to 72% during the second quarter of 2025 as compared to 75% during the same period last year. Technical full-time equivalent employees decreased 2% to 958 during the second quarter of 2025 as compared to 975 during the same period last year.

Three Months Ended July 4, 2025 compared to Three Months Ended June 28, 2024

Revenues

 

 

Three Months Ended

 

 

 

 

(In thousands, except percentages)

 

July 4,
2025

 

 

June 28,
2024

 

 

Percent
Change

 

Engineering and other scientific

 

$

120,980

 

 

$

118,477

 

 

 

2.1

%

Percentage of total revenues

 

 

85.2

%

 

 

84.3

%

 

 

 

Environmental and health

 

 

20,982

 

 

 

22,059

 

 

 

-4.9

%

Percentage of total revenues

 

 

14.8

%

 

 

15.7

%

 

 

 

Total revenues

 

$

141,962

 

 

$

140,536

 

 

 

1.0

%

The increase in revenues for our Engineering and other scientific segment was due to an increase in billing rates offset by a decrease in billable hours. The increase in revenues was driven by demand for our dispute related services in the construction, automotive, and medical device sectors. During the second quarter of 2025, billable hours for this segment decreased by 5% to 291,000 as compared to 306,000 during the same period last year. Utilization for this segment decreased to 74% during the second quarter of 2025 as compared to 77% during the same period last year. Technical full-time equivalent employees in this segment decreased 1% to 756 during the second quarter of 2025 as compared to 765 for the same period last year.

 

The decrease in revenues for our Environmental and health segment was due to a decrease in billable hours partially offset by an increase in billing rates. The decrease in revenues was due to lower levels of activity for proactive projects in the life sciences sector and our chemical regulatory services. During the second quarter of 2025, billable hours for this segment decreased by 9% to 68,000 as compared to 75,000 during the same period last year. Utilization for this segment decreased to 65% during the second quarter of 2025 as compared to 68% during the same period last year. Technical full-time equivalent employees in this segment decreased 4% to 202 as compared to 210 during the same period last year.

Compensation and Related Expenses

 

 

Three Months Ended

 

 

 

 

(In thousands, except percentages)

 

July 4,
2025

 

 

June 28,
2024

 

 

Percent
Change

 

Compensation and related expenses

 

$

97,474

 

 

$

79,466

 

 

 

22.7

%

Percentage of total revenues

 

 

68.7

%

 

 

56.5

%

 

 

 

 

- 21 -


 

The increase in compensation and related expenses during the second quarter of 2025 was due to a change in the value of assets associated with our deferred compensation plan, an increase in payroll expenses from the impact of our annual salary adjustments and an increase in fringe benefits. During the second quarter of 2025, deferred compensation expense increased by $16,088,000 with a corresponding increase to other income, net, as compared to the same period last year, due to the change in value of assets associated with our deferred compensation plan. This increase consisted of an increase in the value of plan assets of $16,963,000 during the second quarter of 2025 as compared to an increase of $875,000 during the same period last year. During the second quarter of 2025 payroll expenses increased $1,003,000 and fringe benefits increased $809,000 due to the impact of our annual salary increase partially offset by a decrease in technical full-time equivalent employees. We expect our compensation expense, excluding the change in value of deferred compensation plan assets, to increase as we selectively add new talent and adjust compensation to market conditions.

Other Operating Expenses

 

 

Three Months Ended

 

 

 

 

(In thousands, except percentages)

 

July 4,
2025

 

 

June 28,
2024

 

 

Percent
Change

 

Other operating expenses

 

$

12,072

 

 

$

11,185

 

 

 

7.9

%

Percentage of total revenues

 

 

8.5

%

 

 

8.0

%

 

 

 

Other operating expenses include facilities-related costs, technical materials, computer-related expenses and depreciation and amortization of property, equipment and leasehold improvements. The increase in other operating expenses during the second quarter of 2025 was primarily due to an increase in occupancy expense of $692,000 and an increase in computer-related expenses of $128,000. Our land lease with the State of Arizona was extended on June 19, 2024. This extension resulted in additional non-cash rent expense of approximately $939,000 during the second quarter of 2025. This increased level of rent expense will continue through the extended lease term ending in January of 2043 with adjustments in 2033 and 2038 based on the consumer price index. The increase in computer-related expenses was due to continued investments in our corporate infrastructure. We expect other operating expenses to grow as we selectively add new talent and make investments in our corporate infrastructure.

Reimbursable Expenses

 

 

Three Months Ended

 

 

 

 

(In thousands, except percentages)

 

July 4,
2025

 

 

June 28,
2024

 

 

Percent
Change

 

Reimbursable expenses

 

$

9,094

 

 

$

8,102

 

 

 

12.2

%

Percentage of total revenues

 

 

6.4

%

 

 

5.8

%

 

 

 

The amount of reimbursable expenses will vary from quarter to quarter depending on the nature of our projects.

General and Administrative Expenses

 

 

Three Months Ended

 

 

 

 

(In thousands, except percentages)

 

July 4,
2025

 

 

June 28,
2024

 

 

Percent
Change

 

General and administrative expenses

 

$

6,145

 

 

$

6,039

 

 

 

1.8

%

Percentage of total revenues

 

 

4.3

%

 

 

4.3

%

 

 

 

The increase in general and administrative expenses was primarily due to an increase in travel and meals of $318,000 and an increase in personnel expenses of $136,000 partially offset by a decrease in legal fees of $382,000. We expect general and administrative expenses to increase as we selectively add new talent and expand our business development and staff development initiatives.

Operating Income

- 22 -


 

 

 

Three Months Ended

 

 

 

 

(In thousands, except percentages)

 

July 4,
2025

 

 

June 28,
2024

 

 

Percent
Change

 

Engineering and other scientific

 

$

42,942

 

 

$

43,765

 

 

 

-1.9

%

Environmental and health

 

 

7,020

 

 

 

7,259

 

 

 

-3.3

%

Total segment operating income

 

 

49,962

 

 

 

51,024

 

 

 

-2.1

%

Corporate operating expense

 

 

(32,785

)

 

 

(15,280

)

 

 

114.6

%

Total operating income

 

$

17,177

 

 

$

35,744

 

 

 

-51.9

%

The decrease in operating income for our Engineering and other scientific segment during the second quarter of 2025 as compared to the same period last year was due to a decrease in utilization and an increase in other operating expenses associated with the extension of our land lease with the State of Arizona. The decrease in operating income for our Environmental and health segment during the second quarter of 2025 was due to a decrease in utilization.

Certain operating expenses are excluded from our measure of segment operating income. These expenses include the costs associated with our human resources, finance, information technology, corporate and business development groups; the deferred compensation expense/benefit due to the change in value of assets associated with our deferred compensation plan; stock-based compensation associated with restricted stock unit and stock option awards; and the change in our allowance for contract losses and doubtful accounts.

The increase in corporate operating expenses during the second quarter of 2025 as compared to the same period last year was primarily due to an increase in deferred compensation expense. During the second quarter of 2025, deferred compensation expense increased $16,088,000, with a corresponding increase to other income, net, as compared to the same period last year, due to the change in value of assets associated with our deferred compensation plan. This increase consisted of an increase in the value of plan assets of $16,963,000 during the second quarter of 2025 as compared to an increase in the value of plan assets of $875,000 during the same period last year.

Other Income, Net

 

 

Three Months Ended

 

 

 

 

(In thousands, except percentages)

 

July 4,
2025

 

 

June 28,
2024

 

 

Percent
Change

 

Other income / (loss), net

 

$

19,638

 

 

$

3,938

 

 

 

398.7

%

Percentage of total revenues

 

 

13.8

%

 

 

2.8

%

 

 

 

Other income, net, consists primarily of changes in the value of assets associated with our deferred compensation plan, interest income earned on available cash, cash equivalents and short-term investments, and rental income from leasing space in our Silicon Valley and Natick facilities. The increase in other income, net, was primarily due to a change in the value of assets associated with our deferred compensation plan partially offset by a decrease in rental income. During the second quarter of 2025, deferred compensation expense increased $16,088,000, with a corresponding increase to other income, net, as compared to the same period last year, due to the change in value of assets associated with our deferred compensation plan. This increase consisted of an increase in the value of plan assets of $16,963,000 during the second quarter of 2025 as compared to an increase in the value of plan assets of $875,000 during the same period last year. During the second quarter of 2025, rental income decreased by $641,000 due to the loss of a tenant in our Silicon Valley facility.

Income Taxes

 

 

Three Months Ended

 

 

 

 

(In thousands, except percentages)

 

July 4,
2025

 

 

June 28,
2024

 

 

Percent
Change

 

Income taxes

 

$

10,262

 

 

$

10,455

 

 

 

-1.8

%

Percentage of total revenues

 

 

7.2

%

 

 

7.4

%

 

 

 

Effective tax rate

 

 

27.9

%

 

 

26.3

%

 

 

 

 

- 23 -


 

During the second quarter of 2025, the tax impact associated with stock-based awards was immaterial as compared to a tax benefit of $726,000 during the same period last year. Excluding the tax impact, the effective tax rate would have been 27.8% during the second quarter of 2025 as compared to 28.2% during the same period last year. The One Big Beautiful Bill Act was enacted on July 4, 2025. The impact of this legislation on our current and deferred tax positions was not material.

 

Six Months Ended July 4, 2025 compared to Six Months Ended June 28, 2024

 

Revenues

 

 

Six Months Ended

 

 

 

 

(In thousands, except percentages)

 

July 4,
2025

 

 

June 28,
2024

 

 

Percent
Change

 

Engineering and other scientific

 

$

243,115

 

 

$

239,948

 

 

 

1.3

%

Percentage of total revenues

 

 

84.6

%

 

 

84.1

%

 

 

 

Environmental and health

 

 

44,354

 

 

 

45,521

 

 

 

-2.6

%

Percentage of total revenues

 

 

15.4

%

 

 

15.9

%

 

 

 

Total revenues

 

$

287,469

 

 

$

285,469

 

 

 

0.7

%

The increase in revenues for our Engineering and other scientific segment was due to an increase in billing rates partially offset by a decrease in billable hours. The increase in revenues was driven by demand for our dispute related services in the construction and automotive sectors. During the first six months of 2025, billable hours for this segment decreased by 5% to 591,000 as compared to 620,000 during the same period last year. Utilization for this segment decreased to 75% during the first six months of 2025 as compared to 77% during the same period last year. Technical full-time equivalent employees in this segment decreased 2% to 759 during the first six months of 2025 as compared to 775 for the same period last year.

 

The decrease in revenues for our Environmental and health segment was due to a decrease in billable hours partially offset by an increase in billing rates. The decrease in revenues was due to a lower level of activity for proactive projects in the life sciences sector. During the first six months of 2025, billable hours for this segment decreased by 5% to 144,000 as compared to 152,000 during the same period last year. Utilization in this segment was flat at 68% during the first six months of 2025 and 2024. Technical full-time equivalent employees in this segment decreased by 5% to 203 during the first six months of 2025 as compared to 214 during the same period last year.

 

Compensation and Related Expenses

 

 

Six Months Ended

 

 

 

 

(In thousands, except percentages)

 

July 4,
2025

 

 

June 28,
2024

 

 

Percent
Change

 

Compensation and related expenses

 

$

173,377

 

 

$

169,793

 

 

 

2.1

%

Percentage of total revenues

 

 

60.3

%

 

 

59.5

%

 

 

 

The increase in compensation and related expenses during the first six months of 2025 was due to an increase in payroll expense, an increase in stock-based compensation, and an increase in fringe benefits. Payroll expense increased by $1,252,000 and fringe benefits increased by $534,000 during the first six months of 2025 due to the impact of our annual salary adjustments partially offset by the decrease in technical full-time equivalent employees. Stock-based compensation expense increased $759,000 during the first six months of 2025 due to an increase in unvested restricted stock unit grants. We expect our compensation expense, excluding the change in value of deferred compensation plan assets, to increase as we selectively add new talent and adjust compensation to market conditions.

 

Other Operating Expenses

 

 

Six Months Ended

 

 

 

 

(In thousands, except percentages)

 

July 4,
2025

 

 

June 28,
2024

 

 

Percent
Change

 

Other operating expenses

 

$

24,167

 

 

$

21,716

 

 

 

11.3

%

Percentage of total revenues

 

 

8.4

%

 

 

7.6

%

 

 

 

 

- 24 -


 

Other operating expenses include facilities-related costs, technical materials, computer-related expenses and depreciation and amortization of property, equipment and leasehold improvements. The increase in other operating expenses during the first six months of 2025 was primarily due to an increase in occupancy expense of $1,684,000 and an increase in computer-related expenses of $463,000. Our land lease with the State of Arizona was extended on June 19, 2024. This extension resulted in additional non-cash rent expense of approximately $2,024,000 during the first six months of 2025. This increased level of rent expense will continue through the extended lease term ending in January of 2043 with adjustments in 2033 and 2038 based on the consumer price index. The increase in computer-related expenses was due to continued investments in our corporate infrastructure. We expect other operating expenses to grow as we selectively add new talent and make investments in our corporate infrastructure.

 

Reimbursable Expenses

 

 

Six Months Ended

 

 

 

 

(In thousands, except percentages)

 

July 4,
2025

 

 

June 28,
2024

 

 

Percent
Change

 

Reimbursable expenses

 

$

17,164

 

 

$

15,828

 

 

 

8.4

%

Percentage of total revenues

 

 

6.0

%

 

 

5.5

%

 

 

 

The amount of reimbursable expenses will vary from quarter to quarter depending on the nature of our projects.

General and Administrative Expenses

 

 

Six Months Ended

 

 

 

 

(In thousands, except percentages)

 

July 4,
2025

 

 

June 28,
2024

 

 

Percent
Change

 

General and administrative expenses

 

$

11,152

 

 

$

11,675

 

 

 

-4.5

%

Percentage of total revenues

 

 

3.9

%

 

 

4.1

%

 

 

 

The decrease in general and administrative expenses was primarily due to a decrease in legal fee of $543,000 and a decrease in bad debt expense of $293,000. The decrease in bad debt expense was due to a decrease in our allowance for bad debt. We expect general and administrative expenses to increase as we expand our business development and staff development initiatives.

Operating Income

 

 

Six Months Ended

 

 

 

 

(In thousands, except percentages)

 

July 4,
2025

 

 

June 28,
2024

 

 

Percent
Change

 

Engineering and other scientific

 

$

88,055

 

 

$

92,396

 

 

 

-4.7

%

Environmental and health

 

 

15,718

 

 

 

15,495

 

 

 

1.4

%

Total segment operating income

 

 

103,773

 

 

 

107,891

 

 

 

-3.8

%

Corporate operating expense

 

 

(42,164

)

 

 

(41,434

)

 

 

1.8

%

Total operating income

 

$

61,609

 

 

$

66,457

 

 

 

-7.3

%

The decrease in operating income for our Engineering and other scientific segment during the first six months of 2025 as compared to the same period last year was due to due to a decrease in utilization and an increase in other operating expenses associated with the extension of our land lease with the State of Arizona.

 

Certain operating expenses are excluded from our measure of segment operating income. These expenses include the costs associated with our human resources, legal, finance, information technology, and business development groups; the deferred compensation expense/benefit due to the change in value of assets associated with our deferred compensation plan; stock-based compensation associated with restricted stock unit and stock option awards; and the change in our allowance for contract losses and doubtful accounts.

 

Other Income, Net

- 25 -


 

 

 

Six Months Ended

 

 

 

 

(In thousands, except percentages)

 

July 4,
2025

 

 

June 28,
2024

 

 

Percent
Change

 

Other income (loss), net

 

$

12,966

 

 

$

13,648

 

 

 

-5.0

%

Percentage of total revenues

 

 

4.5

%

 

 

4.8

%

 

 

 

Other income, net, consists primarily of changes in the value of assets associated with our deferred compensation plan, interest income earned on available cash, cash equivalents and short-term investments, and rental income from leasing space in our Silicon Valley and Natick facilities. The decrease in other income, net, was primarily due to a decrease in rental income partially offset by a change in the value of assets associated with our deferred compensation plan. During the first six months of 2025, rental income decreased by $1,293,000 due to the loss of a tenant in our Silicon Valley facility. During the first six months of 2025, deferred compensation expense increased $485,000 with a corresponding increase to other income, net, as compared to the same period last year, due to the change in value of assets associated with our deferred compensation plan. This increase consisted of increase in the value of plan assets of $7,627,000 during the first six months of 2025 as compared to an increase in the value of plan assets of $7,142,000 during the same period last year.

Income Taxes

 

 

Six Months Ended

 

 

 

 

(In thousands, except percentages)

 

July 4,
2025

 

 

June 28,
2024

 

 

Percent
Change

 

Income taxes

 

$

21,372

 

 

$

20,736

 

 

 

3.1

%

Percentage of total revenues

 

 

7.4

%

 

 

7.3

%

 

 

 

Effective tax rate

 

 

28.7

%

 

 

25.9

%

 

 

 

During the first six months of 2025, we realized a negative tax impact associated with stock-based awards of $485,000 as compared to a positive tax benefit of $1,672,000 during the same period last year. The change in the tax impact associated with stock-based awards was due to the change in the difference of the value of our common stock between the grant date and the release date for the restricted stock units released during the first six months of 2025 as compared to the same period last year. Excluding the tax impact, the effective tax rate would have been 28.0% during the first six months of 2025 and 2024.

LIQUIDITY AND CAPITAL RESOURCES

 

We believe our existing balances of cash, cash equivalents, and cash generated from operations will be sufficient to satisfy our working capital needs, capital expenditures, outstanding commitments, stock repurchases, dividends and other liquidity requirements over at least the next twelve months.

 

 

 

Six Months Ended

 

(In thousands)

 

July 4,
2025

 

 

June 28,
2024

 

Net cash provided by operating activities

 

$

43,496

 

 

$

58,771

 

Net cash used in by investing activities

 

 

(4,028

)

 

 

(2,628

)

Net cash used in financing activities

 

 

(67,517

)

 

 

(39,829

)

 

We financed our business during the first six months of 2025 through available cash. As of July 4, 2025, our cash and cash equivalents were $231,801,000 as compared to $258,901,000 at January 3, 2025.

Generally, our net cash provided by operating activities is used to fund our day to day operating activities. First quarter operating cash requirements are generally higher due to payment in the first quarter of our annual bonuses accrued during the prior year. Our largest source of operating cash flows is collections from our clients. Our primary uses of cash from operating activities are for employee related expenditures, leased facilities, taxes, and general operating expenses.

- 26 -


 

The increase in net cash used in investing activities during the first six months of 2025, as compared to the same period last year, was due to an increase in capital expenditures. The increase in capital expenditures was due to an increase in investment in our corporate infrastructure.

The increase in net cash used in financing activities during the first six months of 2025, as compared to the same period last year was due to an increase in repurchases of our common stock.

We lease office, laboratory, and storage space in 13 states and the District of Columbia, as well as in China, Germany, Hong Kong, Ireland, Singapore, Switzerland, and the United Kingdom under non-cancellable operating lease arrangements that expire at various dates through 2033. On June 19, 2024, we entered into an agreement with the State of Arizona to extend our land lease for 15 years beginning on January 17, 2028. We are currently obligated to make payments under the lease of $1,009,000 per year, which obligation will continue at that level until January 16, 2028. Beginning on January 17, 2028, our payments under the lease will increase to approximately $6,183,000 per year for the 15-year extension term with adjustments to the annual rent payment in 2033 and 2038 based on the consumer price index.

We expect to continue our investing activities, including capital expenditures. Furthermore, cash reserves may be used to repurchase shares of common stock under our stock repurchase programs, pay dividends, or strategically acquire professional service firms that are complementary to our business.

We maintain a nonqualified deferred compensation plan for the benefit of a select group of highly compensated employees. Vested amounts due under the plan of $117,555,000 were recorded as a long-term liability on our unaudited condensed consolidated balance sheet at July 4, 2025. Vested amounts due under the plan of $17,386,000 were recorded as a current liability on our unaudited condensed consolidated balance sheet at July 4, 2025. Our assets that are earmarked to pay benefits under the plan are held in a rabbi trust and are subject to the claims of our creditors. As of July 4, 2025, invested amounts under the plan of $114,929,000 were recorded as a long-term asset on our unaudited condensed consolidated balance sheet. As of July 4, 2025, invested amounts under the plan of $17,386,000 were recorded as a current asset on our unaudited condensed consolidated balance sheet.

As permitted under Delaware law, we have agreements whereby we indemnify our officers and directors for certain events or occurrences while the officer or director is, or was serving, at our request in such capacity. The indemnification period covers all pertinent events and occurrences during the officer’s or director’s lifetime. The maximum potential amount of future payments we could be required to make under these indemnification agreements is unlimited; however, we have director and officer insurance coverage that reduces our exposure and enables us to recover a portion of any future amounts paid. We believe the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is minimal.

Non-GAAP Financial Measures

Regulation G, Conditions for Use of Non-Generally Accepted Accounting Principles ("Non-GAAP") Financial Measures, and other U.S. Securities and Exchange Commission (“SEC”) rules and regulations define and prescribe the conditions for use of Non-GAAP financial information. Generally, a Non-GAAP financial measure is a numerical measure of a company's performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. We closely monitor two financial measures, EBITDA and EBITDAS, which meet the definition of Non-GAAP financial measures. We define EBITDA as net income before income taxes, net interest income, depreciation and amortization. We define EBITDAS as EBITDA before stock-based compensation. The Company regards EBITDA and EBITDAS as useful measures of operating performance to complement operating income, net income and other GAAP financial performance measures. Additionally, management believes that EBITDA and EBITDAS provide meaningful comparisons of past, present and future operating results. These measures are used to evaluate our financial results, develop budgets and determine employee compensation. These measures, however, should be considered in addition to, and not as a substitute for or superior to, operating income, cash flows, or other measures of financial performance prepared in accordance with GAAP. A reconciliation of the Non-GAAP measures to the nearest comparable GAAP measure is set forth below.

- 27 -


 

The following table shows EBITDA (determined as shown in the reconciliation table below) as a percentage of revenues before reimbursements for the three and six months ended July 4, 2025 and June 28, 2024:

 

 

 

Three Months Ended

 

 

Six Months Ended

 

(In thousands, except percentages)

 

July 4,
2025

 

 

June 28,
2024

 

 

July 4,
2025

 

 

June 28,
2024

 

Revenues before reimbursements

 

$

132,868

 

 

$

132,434

 

 

$

270,305

 

 

$

269,641

 

EBITDA

 

$

36,991

 

 

$

39,937

 

 

$

74,529

 

 

$

80,058

 

EBITDA as a % of revenues before
   reimbursements

 

 

27.8

%

 

 

30.2

%

 

 

27.6

%

 

 

29.7

%

The decrease in EBITDA as a percentage of revenues before reimbursements during the three and six months ended July 4, 2025 as compared to the same periods last year was primarily due to a decrease in utilization, an increase in payroll expense from annual salary adjustments, an increase in occupancy expense associated with the extension of our land lease with the State of Arizona and a decrease in rental income due to the loss of a tenant in our Silicon Valley facility.

 

The following table is a reconciliation of EBITDA and EBITDAS to the most comparable GAAP measure, net income, for the three and six months ended July 4, 2025 and June 28, 2024:

 

 

 

Three Months Ended

 

 

Six Months Ended

 

(In thousands)

 

July 4,
2025

 

 

June 28,
2024

 

 

July 4,
2025

 

 

June 28,
2024

 

Net income

 

$

26,553

 

 

$

29,227

 

 

$

53,203

 

 

$

59,369

 

Add back (subtract):

 

 

 

 

 

 

 

 

 

 

 

 

Income taxes

 

 

10,262

 

 

 

10,455

 

 

 

21,372

 

 

 

20,736

 

Interest income, net

 

 

(2,344

)

 

 

(2,231

)

 

 

(5,058

)

 

 

(4,857

)

Depreciation and amortization

 

 

2,520

 

 

 

2,486

 

 

 

5,012

 

 

 

4,810

 

EBITDA

 

 

36,991

 

 

 

39,937

 

 

 

74,529

 

 

 

80,058

 

Stock-based compensation

 

 

5,246

 

 

 

5,577

 

 

 

13,426

 

 

 

12,917

 

EBITDAS

 

$

42,237

 

 

$

45,514

 

 

$

87,955

 

 

$

92,975

 

 

- 28 -


 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to interest rate risk associated with our balances of cash and cash equivalents. We manage our interest rate risk by maintaining an investment portfolio primarily consisting of debt instruments with high credit quality and relatively short average effective maturities in accordance with our investment policy. The maximum effective maturity of any issue in our portfolio is 3 years and the maximum average effective maturity of the portfolio cannot exceed 12 months. If interest rates were to instantaneously increase or decrease by 100 basis points, the change in the fair market value of our portfolio of cash equivalents would not have a material impact on our financial statements. We do not use derivative financial instruments in our portfolio. There have not been any material changes during the period covered by this Quarterly Report on Form 10-Q to our interest rate risk exposures, or how these exposures are managed. Notwithstanding our efforts to manage interest rate risk, there can be no assurances that we will be adequately protected against the risks associated with interest rate fluctuations.

We have foreign currency risk related to our revenues and expenses denominated in currencies other than the U.S. dollar, primarily the British Pound, the Euro, the Chinese Yuan, and the Hong Kong Dollar. Accordingly, changes in exchange rates may negatively affect the revenues and net income of our foreign subsidiaries as expressed in U.S. dollars.

At July 4, 2025, we had net assets of approximately $10.8 million with a functional currency of the British Pound, net assets of approximately $2.7 million with a functional currency of the Chinese Yuan, net assets of approximately $1.7 million with a functional currency of the Hong Kong Dollar, and net assets of approximately $1.7 million with a functional currency of the Singapore Dollar associated with our operations in the United Kingdom, China, Hong Kong, and Singapore, respectively.

We also have foreign currency risk related to foreign currency transactions and monetary assets and liabilities denominated in currencies that are not the functional currency. We have experienced and will continue to experience fluctuations in our net income as a result of gains (losses) on these foreign currency transactions and the remeasurement of monetary assets and liabilities. At July 4, 2025, we had net assets denominated in the non-functional currency of approximately $3.4 million.

We do not use foreign exchange contracts to hedge any foreign currency exposures. To date, the impacts of foreign currency exchange rate changes on our consolidated revenues and consolidated net income have not been significant. However, our continued international growth increases our exposure to exchange rate fluctuations and as a result such fluctuations could have a significant impact on our future results of operations.

Item 4. Controls and Procedures

(a)
Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended, an evaluation was performed under the supervision and with the participation of the Company’s management, including the Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this quarterly report. Based on that evaluation, the Company’s management, including the Chief Executive Officer and the Chief Financial Officer, concluded that, as of July 4, 2025, the Company’s disclosure controls and procedures were effective.

We review and evaluate the design and effectiveness of our disclosure controls and procedures on an ongoing basis, to improve our controls and procedures over time and to correct any deficiencies that we may discover in the future. Our goal is to ensure that our senior management has timely access to all material financial and non-financial information concerning our business. While we believe the present design of our disclosure controls and procedures is effective to achieve our goal, future events affecting our business may cause us to significantly modify our disclosure controls and procedures.

(b)
Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the three-month period ended July 4, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

- 29 -


 

PART II - OTHER INFORMATION

Exponent is not engaged in any material legal proceedings.

Item 1A. Risk Factors

There have been no material changes from risk factors as previously discussed under the heading “Risk Factors” in the Company’s 2024 Annual Report.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table provides information on the Company’s repurchases of the Company’s common stock for the three months ended July 4, 2025:

 

(In thousands, except price per share)

 

Total
Number
of Shares
Purchased

 

 

Average
Price
Paid Per
Share

 

 

Total
Number of
Shares
Purchased
as Part of
Publicly
Announced
Programs

 

 

Approximate
Dollar Value
of Shares That
May Yet Be
Purchased
Under the
Programs
(1)

 

April 5 to May 2

 

 

102

 

 

$

74.94

 

 

 

102

 

 

$

81,610

 

May 3 to May 30

 

 

-

 

 

 

-

 

 

 

-

 

 

 

81,610

 

May 31 to July 4

 

 

263

 

 

 

75.95

 

 

 

263

 

 

 

61,610

 

Total

 

 

365

 

 

$

75.66

 

 

 

365

 

 

$

61,610

 

 

(1)
On February 22, 2022, the Company’s Board of Directors announced $150,000,000 for repurchase of the Company’s common stock. On February 1, 2024, the Company's Board of Directors announced an additional $61,610,000 for repurchase of the Company's common stock. These repurchase programs have no expiration date.

Repurchases of the Company’s common stock were affected pursuant to a repurchase program authorized by the Company’s Board of Directors.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Rule 10b5-1 Plans

The following table summarizes the adoption by the Company’s directors and officers of trading plans intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) during the three months ended July 4, 2025:

Name and Title

Adoption Date

Expiration Date

Aggregate Number of Securities to be Sold (1)

 

Aggregate Number of Securities to be Purchased

Catherine Ford Corrigan, President and Chief Executive Officer

May 15, 2025

August 30, 2026

16,128

 

0

 

 

- 30 -


 

(1)
Does not include an additional indeterminable number of shares permitted to be sold pursuant to the Rule 10b5-1 (c) trading arrangement in order to satisfy tax obligations related to stock option exercises.

During the three months ended July 4, 2025, no pre-existing trading plans intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) were modified or terminated by the Company’s directors and officers, and no other written trading arrangements that are not intended to qualify for the Rule 10b5-1(c) affirmative defense were adopted, modified, or terminated by the Company’s directors and officers.

 

- 31 -


 

Item 6. Exhibits

(a)
Exhibit Index

 

  31.1

Certification of Chief Executive Officer pursuant to Rule 13a – 14(a) under the Securities Exchange Act of 1934.

 

 

  31.2

Certification of Chief Financial Officer pursuant to Rule 13a – 14(a) under the Securities Exchange Act of 1934.

 

 

  32.1

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.

 

 

  32.2

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.

 

 

101.INS

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

 

 

101.SCH

Inline XBRL Taxonomy Extension Schema Embedded Linkbase Documents

 

 

Exhibit 104

Cover page formatted as Inline XBRL and contained in Exhibit 101

 

- 32 -


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

EXPONENT, INC.

 

 

(Registrant)

 

 

 

Date: August 8, 2025

 

 

 

 

/s/ Catherine Ford Corrigan

 

 

Catherine Ford Corrigan, Ph.D., Chief Executive Officer

 

 

 

 

 

 

 

 

/s/ Richard L. Schlenker

 

 

Richard L. Schlenker, Chief Financial Officer

 

- 33 -



ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

EX-31.1

EX-31.2

EX-32.1

EX-32.2

XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT

IDEA: R1.htm

IDEA: R2.htm

IDEA: R3.htm

IDEA: R4.htm

IDEA: R5.htm

IDEA: R6.htm

IDEA: R7.htm

IDEA: R8.htm

IDEA: R9.htm

IDEA: R10.htm

IDEA: R11.htm

IDEA: R12.htm

IDEA: R13.htm

IDEA: R14.htm

IDEA: R15.htm

IDEA: R16.htm

IDEA: R17.htm

IDEA: R18.htm

IDEA: R19.htm

IDEA: R20.htm

IDEA: R21.htm

IDEA: R22.htm

IDEA: R23.htm

IDEA: R24.htm

IDEA: R25.htm

IDEA: R26.htm

IDEA: R27.htm

IDEA: R28.htm

IDEA: R29.htm

IDEA: R30.htm

IDEA: R31.htm

IDEA: R32.htm

IDEA: R33.htm

IDEA: R34.htm

IDEA: R35.htm

IDEA: R36.htm

IDEA: R37.htm

IDEA: R38.htm

IDEA: R39.htm

IDEA: R40.htm

IDEA: R41.htm

IDEA: R42.htm

IDEA: R43.htm

IDEA: R44.htm

IDEA: R45.htm

IDEA: R46.htm

IDEA: R47.htm

IDEA: R48.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: expo-20250704_htm.xml